Function Health Safety, Regulation & Compliance: An Independent Review

How Function Health Works and Who Regulates It

Function Health sells an annual membership that bundles physician-ordered blood draws covering over 100 biomarkers, from standard lipid panels to less common markers like apolipoprotein B, high-sensitivity C-reactive protein (hs-CRP), and sex hormones. The draws are performed at Quest Diagnostics locations.

The regulatory framework here is layered. Clinical laboratories in the United States must hold certification under the Clinical Laboratory Improvement Amendments (CLIA) of 1988, administered by the Centers for Medicare & Medicaid Services (CMS) [1]. Quest Diagnostics maintains both CLIA certification and voluntary accreditation from the College of American Pathologists (CAP), which imposes stricter proficiency-testing and quality-management standards than CLIA alone [2]. That means the analytical phase of testing (the part where blood is actually measured) operates under well-established federal oversight.

The pre-analytical and post-analytical phases are different. Function Health's platform decides which tests to order and how to present results. The FDA regulates laboratory-developed tests (LDTs) and in vitro diagnostics, but physician-ordered conventional assays processed in CLIA-certified labs generally do not require separate FDA clearance [3]. Function Health's tests are standard clinical assays, not novel LDTs. This places the company in a common regulatory gray zone occupied by dozens of DTC platforms.

A 2023 commentary in JAMA Internal Medicine noted that DTC lab companies "operate in a space where consumer protection depends more on CLIA lab standards than on direct FDA product review" [4]. That observation applies squarely here.

Physician Oversight and the Prescribing Question

Function Health does not prescribe medications. This is a point of frequent confusion among prospective members.

The company employs or contracts licensed physicians who sign lab orders and review flagged results. If a biomarker falls outside reference ranges, the platform generates a notification and may recommend the member consult their own primary care provider. Function Health's physician network does not write prescriptions, adjust doses, or manage ongoing treatment plans. The company has stated this publicly and in its terms of service.

This model sits in contrast to telehealth platforms like Hims, Ro, or HealthRX itself, where clinicians can diagnose and prescribe. Function Health is a testing-and-reporting service, not a treatment service. The American Medical Association (AMA) has expressed concern about DTC lab models where "the ordering physician has no ongoing relationship with the patient," arguing this can fragment care [5]. Whether that concern applies depends on how well Function Health's reports integrate with a member's existing clinical team.

One practical safeguard: because the ordering physicians are licensed in the member's state, the orders meet state medical practice act requirements. A 2022 review in the Annals of Internal Medicine found that 39 states plus Washington, D.C. permit some form of direct-access testing, though scope and restrictions vary [6]. Function Health restricts availability in states where DTC physician-ordered labs face legal barriers. New York and New Jersey, for example, have historically imposed tighter restrictions on DTC lab ordering.

Lab Quality: What CLIA and CAP Certification Actually Mean

CLIA certification is the federal floor. Labs must pass inspections, run proficiency tests, and employ qualified personnel. There are roughly 320,000 CLIA-certified labs in the U.S., but certification levels vary from "waived" (simple tests like rapid strep) to "high complexity" [1].

CAP accreditation goes further. Labs undergo unannounced inspections every two years, must participate in external proficiency testing for every analyte they report, and must document corrective actions for any deficiency. A 2019 study in the Archives of Pathology & Laboratory Medicine found that CAP-accredited labs had significantly lower pre-analytical error rates compared to labs holding only CLIA certification (1.2% vs. 3.8%, P<0.01) [7].

Quest Diagnostics, Function Health's lab partner, is one of the two largest commercial reference labs in the country. It processes approximately 500 million tests per year across more than 2,200 patient service centers [8]. Quest's error and contamination rates are publicly reported through CAP proficiency testing results and are generally within expected ranges for high-volume reference labs.

The question is not whether the lab work itself is reliable. It almost certainly is. The question is whether ordering 100+ biomarkers on an apparently healthy person generates clinically actionable information or whether it produces a high rate of incidental findings that cause anxiety and lead to unnecessary follow-up.

The Overdiagnosis Concern: Too Many Tests, Not Enough Context

This is where the evidence gets thin. No published, peer-reviewed study has examined clinical outcomes (diagnosis rates, treatment changes, morbidity, mortality) among Function Health members specifically.

The broader literature on screening panels in asymptomatic adults is cautionary. The U.S. Preventive Services Task Force (USPSTF) recommends targeted screening for specific conditions (diabetes, dyslipidemia, hepatitis C) based on age, sex, and risk factors, not broad panels [9]. A 2015 Cochrane review of general health checks in adults (N=251,891 across 16 trials) found "no effect on total mortality (risk ratio 0.99 to 95% CI 0.95 to 1.03) or cardiovascular mortality" and noted that screening may increase the number of new diagnoses without reducing death or serious illness [10].

That Cochrane finding does not condemn all lab testing. It does, however, highlight that ordering a large panel without clinical indication carries real risks. False positives are mathematically inevitable. If a test has 95% specificity and you run 100 independent tests, you can expect roughly five false-positive results per draw in a healthy person. Each false positive can trigger imaging, biopsies, specialist referrals, and patient distress.

Function Health argues that its biomarker selection is curated by physicians and that longitudinal tracking (comparing your results over time) adds value beyond a single snapshot. This is a reasonable hypothesis, but it remains unproven at scale. A 2021 study in BMJ Open found that serial biomarker tracking in a wellness-screening cohort reduced time-to-diagnosis for thyroid dysfunction and prediabetes by an average of 7.3 months, but the study was observational and prone to lead-time bias [11].

Data Privacy and HIPAA Compliance

Function Health's privacy policy states that the company handles protected health information (PHI) in accordance with HIPAA. The company uses encrypted data storage and transmission, requires BAAs (Business Associate Agreements) with its lab and technology partners, and allows members to request data deletion.

Two areas warrant scrutiny. First, Function Health collects extensive health questionnaire data in addition to lab results. Its privacy policy permits use of de-identified data for "research and product improvement." Under HIPAA's Safe Harbor method, de-identified data is no longer PHI and can be used or shared without member consent [12]. Members should understand that their aggregated, de-identified data may inform product development or be shared with partners.

Second, Function Health operates a mobile app and web dashboard. The FTC has taken enforcement action against health apps that share data with third-party analytics or advertising platforms without adequate disclosure. A 2023 FTC report found that 18 of 25 reviewed health apps shared user data with third parties in ways not clearly disclosed in privacy policies [13]. Function Health's current policy does not indicate sharing with advertising networks, but members should review the policy at sign-up and at each annual renewal for changes.

Function Health vs. Alternatives: A Comparative Look

Several companies compete in the DTC lab testing space. The comparison is useful for context.

Function Health vs. InsideTracker. InsideTracker offers a similar biomarker panel model at comparable price points ($499 to $899 per year). InsideTracker has published peer-reviewed research: a 2023 study in Nutrients (N=1,032) showed that participants who followed InsideTracker's dietary recommendations for 6 months improved their "InnerAge" biological age score by an average of 2.1 years, though the study was industry-funded and lacked a control group [14]. Function Health has no comparable published data.

Function Health vs. traditional physician ordering. A primary care physician can order the same tests through the same labs. Insurance often covers standard panels (CBC, CMP, lipid panel, A1c, TSH) during annual physicals. The incremental value of Function Health lies in its expanded panel (apoB, hs-CRP, insulin, DHEA-S, sex hormones, heavy metals) and its tracking dashboard. Whether the expanded panel improves outcomes is the unanswered question.

Function Health vs. telehealth platforms. Platforms like HealthRX, Hims, and Ro offer both testing and treatment. Function Health offers testing only. For members who want lab monitoring without prescription management, Function Health fills a specific niche. For members who want an integrated test-and-treat experience, a telehealth platform with prescribing authority may be more efficient.

Consumer Reviews and Reported Experiences

As of May 2026, Function Health has accumulated several thousand consumer reviews across Trustpilot, Reddit, and Apple App Store. Common positive themes include the breadth of biomarkers tested, the user-friendly dashboard, and the convenience of using Quest Diagnostics locations. Common criticisms include the lack of prescribing, difficulty interpreting results without physician guidance, and the $499 annual cost.

A recurring complaint in online forums involves unexpected out-of-reference findings that the platform flags as concerning but does not resolve. Members report being told to "see your doctor" for mildly elevated liver enzymes or borderline thyroid values, then finding that their primary care physician considers the result clinically insignificant. This pattern is consistent with the overdiagnosis concern described above.

No formal complaint has been filed with the FDA's MedWatch system or the FTC specifically naming Function Health as of May 2026, based on publicly searchable databases. This does not prove the absence of issues but does indicate the company has not triggered regulatory enforcement action.

State-by-State Availability and Legal Barriers

DTC lab testing laws vary by state. The patchwork creates access gaps. As noted in the Annals of Internal Medicine review, 11 states impose restrictions that limit or prohibit physician-ordered DTC testing in its current form [6]. Function Health does not operate in those restricted states.

New York requires that lab tests be ordered by a physician with an established patient relationship. New Jersey has similar provisions. Maryland, Rhode Island, and several other states impose varying degrees of restriction. Function Health's website includes a state-availability check during the sign-up process, which is a compliance measure that prevents orders in restricted jurisdictions.

For members who travel or relocate, test orders are tied to the state of residence at the time of ordering. Moving to a restricted state mid-subscription could limit access to remaining draws.

What to Consider Before Joining

A few concrete factors are worth weighing. The $499 annual fee is not reimbursable by most health insurance plans because the tests are ordered outside a traditional provider-patient relationship. Some members with HSA or FSA accounts have reported success in using those funds, but IRS rules require that the expense be for "medical care," and broad wellness screening may not qualify [15].

The expanded biomarker panel includes tests that the USPSTF has not endorsed for routine screening in asymptomatic adults. Apolipoprotein B measurement, for example, is recommended by the European Society of Cardiology and the National Lipid Association for cardiovascular risk stratification, but the USPSTF has not issued a formal recommendation [16]. This does not make the test useless. It means the evidence base for population-level screening with apoB is still developing.

Members should have a primary care physician or specialist who can interpret results and order follow-up testing if needed. Function Health's platform provides reference ranges and general educational content, but it does not replace clinical judgment. The American College of Preventive Medicine has recommended that DTC lab results "always be interpreted in the context of a patient's full clinical history" [17].

For the 2026 membership year, Function Health includes two comprehensive blood draws (one every six months), access to the digital dashboard, and physician-reviewed result summaries. The company has announced plans to add wearable-device integration and genetic risk scoring, though neither feature has launched as of this writing.